REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Julie Dardare; Andréa Witz; Alexandre Harlé

doi:10.21037/tlcr-24-144

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Transl Lung Cancer Res. 2024 Aug 31;13(8):2082-2086. doi: 10.21037/tlcr-24-144. Epub 2024 Jul 26.

Authors

Julie Dardare¹, Andréa Witz^{1

2}, Alexandre Harlé^{1

2}

Affiliations

¹ Service de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
² Université de Lorraine, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 7039 Centre de Recherche en Automatique de Nancy (CRAN), Nancy, France.

No abstract available

Keywords: Epidermal growth factor receptor (EGFR); REGN5093-M114; mesenchymal epithelial transition (MET); non-small cell lung cancer (NSCLC); resistance.

Publication types

Editorial
Comment